Genomic medicine: Bringing biomarkers to clinical medicine

Current Opinion in Chemical Biology

Volumn 9, Issue 4, 2005, Pages 381-386

  Seo, David ^a   Ginsburg, Geoffrey S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ASSAY; CLINICAL MEDICINE; DISEASE COURSE; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC VARIABILITY; GENOME; GENOMICS; HEALTH; HUMAN; METABOLOMICS; PHARMACOGENOMICS; POPULATION GENETICS; PREDICTION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SCIENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CLINICAL MEDICINE; GENETIC MARKERS; GENOMICS; HUMANS; PHARMACOGENETICS;

EID: 22544449287     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2005.06.009     Document Type: Review

References (40)

1. J. Bell Predicting disease using genomics Nature 429 2004 453 456
2. S. Hanash Disease proteomics Nature 422 2003 226 232
3. S.M. Ibrahim, and R. Gold Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr Opin Neurol 18 2005 231 235
4. D.G. Robertson Metabonomics in toxicology: a review Toxicol Sci 85 2005 809 822
5. M.J. Werf, R.H. Jellema, and T. Hankemeier Microbial metabolomics: replacing trial-and-error by the unbiased selection and ranking of targets J Ind Microbiol Biotechnol 2005 DOI: 10.1007/s10295-005-0231-4
6. E. Huang, S.H. Cheng, H. Dressman, J. Pittman, M.H. Tsou, C.F. Horng, A. Bild, E.S. Iversen, M. Liao, and C.M. Chen Gene expression predictors of breast cancer outcomes Lancet 361 2003 1590 1596
7. J.N. Rich, C. Hans, B. Jones, E.S. Iversen, R.E. McLendon, B.K. Rasheed, A. Dobra, H.K. Dressman, D.D. Bigner, J.R. Nevins, and M. West Gene expression profiling and genetic markers in glioblastoma survival Cancer Res 65 2005 4051 4058
8. J. Pittman, E. Huang, H. Dressman, C.F. Horng, S.H. Cheng, M.H. Tsou, C.M. Chen, A. Bild, E.S. Iversen, and A.T. Huang Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes Proc Natl Acad Sci USA 101 2004 8431 8436 This paper is one of the first to describe methods for developing models that incorporate both clinical and genomic information. This approach could be utilized to develop usable clinical tools for patient care.
9. L. Kruglyak, and D.A. Nickerson Variation is the spice of life Nat Genet 27 2001 234 236
10. E. Lai Application of SNP technologies in medicine: lessons learned and future challenges Genome Res 11 2001 927 929
11. S. McElroy, C. Sachse, J. Brockmoller, J. Richmond, M. Lira, D. Friedman, I. Roots, B.M. Silber, and P.M. Milos CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting AAPS PharmSci 2 2000 E33
12. L.D. Bradford, and W.G. Kirlin Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology Int J Neuropsychopharmcol 1 1998 173 185
13. R.S. Williams, and P.J. Goldschmidt-Clermont The genetics of cardiovascular disease: from genotype to phenotype Dialogues in Cardiovascular Medicine 9 2004 3 19
14. D. Seo, T. Wang, H. Dressman, E.E. Herderick, E.S. Iversen, C. Dong, K. Vata, C.A. Milano, F. Rigat, and J. Pittman Gene expression phenotypes of atherosclerosis Arterioscler Thromb Vasc Biol 24 2004 1922 1927
15. A. Berchuck, E.S. Iversen, J.M. Lancaster, J. Pittman, J. Luo, P. Lee, S. Murphy, H.K. Dressman, P.G. Febbo, and M. West Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers Clin Cancer Res 11 2005 3686 3696
16. T.R. Golub, D.K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, J.P. Mesirov, H. Coller, M.L. Loh, J.R. Downing, and M.A. Caligiuri Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286 1999 531 537
17. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, M. Cronin, F.L. Baehner, M.G. Walker, D. Watson, and T. Park A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826
18. B. Marte Proteomics Nature 422 2003 191
19. R. Aebersold, and M. Mann Mass spectrometry-based proteomics Nature 422 2003 198 207
20. L. Zhang, W. Yu, T. He, J. Yu, R.E. Caffrey, E.A. Dalmasso, S. Fu, T. Pham, J. Mei, and J.J. Ho Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor Science 298 2002 995 1000
21. G.L. Perkins, E.D. Slater, G.K. Sanders, and J.G. Prichard Serum tumor markers Am Fam Physician 68 2003 1075 1082
22. J. Danesh, J.G. Wheeler, G.M. Hirschfield, S. Eda, G. Eiriksdottir, A. Rumley, G.D. Lowe, M.B. Pepys, and V. Gudnason C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 2004 1387 1397
23. J.A. de Lemos, and D.A. Morrow Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes Rev Cardiovasc Med 4 Suppl 4 2003 S37 S46
24. J.K. Nicholson, and I.D. Wilson Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism Nat Rev Drug Discov 2 2003 668 676
25. R. Goodacre, S. Vaidyanathan, W.B. Dunn, G.G. Harrigan, and D.B. Kell Metabolomics by numbers: acquiring and understanding global metabolite data Trends Biotechnol 22 2004 245 252
26. A.R. Fernie, R.N. Trethewey, A.J. Krotzky, and L. Willmitzer Metabolite profiling: from diagnostics to systems biology Nat Rev Mol Cell Biol 5 2004 763 769
27. J.T. Brindle, H. Antti, E. Holmes, G. Tranter, J.K. Nicholson, H.W. Bethell, S. Clarke, P.M. Schofield, E. McKilligin, and D.E. Mosedale Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics Nat Med 8 2002 1439 1444
28. J.T. Brindle, J.K. Nicholson, P.M. Schofield, D.J. Grainger, and E. Holmes Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension Analyst 128 2003 32 36
29. W.E. Evans, and M.V. Relling Pharmacogenomics: translating functional genomics into rational therapeutics Science 286 1999 487 491
30. U.A. Meyer, and U.M. Zanger Molecular mechanisms of genetic polymorphisms of drug metabolism Annu Rev Pharmacol Toxicol 37 1997 269 296
31. A.D. Roses Pharmacogenetics and drug development: the path to safer and more effective drugs Nat Rev Genet 5 2004 645 656
32. D.A. Hosford, E.H. Lai, J.H. Riley, C.F. Xu, T.M. Danoff, and A.D. Roses Pharmacogenetics to predict drug-related adverse events Toxicol Pathol 32 Suppl 1 2004 9 12
33. P.W. Norbert, and A.D. Roses Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications J Mol Med 81 2003 135 140
34. Foxa KAA, S.G. Goodmanb, F.A. Anderson Jr., C.B. Grangerd, M. Moscuccie, M.D. Flatherf, F. Spencerc, A. Budajg, O.H. Dabbousc, and J.M. Gorec From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24 2003 1414 1424
35. E.M. Ohman, C.B. Granger, R.A. Harrington, and K.L. Lee Risk stratification and therapeutic decision making in acute coronary syndromes J Am Med Assoc 284 2000 876 878
36. W.A. Colburn Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development J Clin Pharmacol 40 2000 1419 1427
37. J.K. Aronson Biomarkers and surrogate endpoints Br J Clin Pharmacol 59 2005 491 494
38. N.M. Morel, J.M. Holland, J. van der Greef, E.W. Marple, C. Clish, J. Loscalzo, and S. Naylor Primer on medical genomics. Part XIV: Introduction to systems biology-a new approach to understanding disease and treatment Mayo Clin Proc 79 2004 651 658
39. M. Tyers, and M. Mann From genomics to proteomics Nature 422 2003 193 197 This is an excellent review of the recent development of proteomics and the interface with genomic research.
40. E.W. Clayton Ethical, legal, and social implications of genomic medicine N Engl J Med 349 2003 562 569 This is an in-depth discussion of the public policy challenges for translating genomic information to patient care.